Bli medlem
Bli medlem

Du är här

2017-01-26

Solon Eiendom ASA : Primary insider notification - Cecilie Grue

Solon Eiendom ASA

STOCK EXCHANGE ANNOUNCEMENT

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR
INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES

Primary insider notification - Cecilie Grue

(Oslo, Norway, 26 January 2017) Reference is made to the announcement on 13
January 2017 by Solon Eiendom ASA ("Solon" or the "Company", ticker "SOLON")
regarding the primary insider notification from certain primary insiders of
the Company that have received Subscription Rights in the Rights Issue.

Grue Invest AS a company wholly owned by Cecilie Grue, a primary insider of
the Company, exercised 196,102 Subscription Rights at a subscription price of
NOK 0,15 per share in the Rights Issue on 25 January 2017. Following
completion of the Rights Issue Grue through Grue Invest AS will hold 497,201
Shares in the Company.

Further information
Simen Thorsen
Chairman of the Board, Solon Eiendom ASA
E-mail:st@soloneiendom.noCell Phone: +47 918 86 886
Andreas Martinussen
Chief Executive Officer, Solon Eiendom ASA
E-mail:am@soloneiendom.noCell Phone: +47 400 00 405

About Solon Eiendom
Solon Eiendom is a Norwegian residential real estate development company
focusing on the Oslo and Akershus region. Solon Eiendom was established in
2006 by founder Simen Thorsen and investor Tore Aksel Voldberg. The company
has since its incorporation delivered 570 units with a corresponding sales
value of close to NOK ~3 billion and sold more than 800 units with a total
sales price of more than NOK ~4 billion. Solon is listed on Oslo Børs
(OSE:SOLON). More information about Solon is available atwww.soloneiendom.no.
About Bionor
Bionor Pharma's mission is to enable the immune system to fight HIV infection.
Bionor is the first company, which has successfully completed a clinical
trial using the shock and kill approach, thereby creating a strong foundation
for further advancing its therapeutic vaccine Vacc-4x in combination with
other agents towards a functional cure. The company believes it has first
mover potential based on clinical results to date and early adoption of the
shock and kill strategy. In December 2015, Bionor announced that the HIV
trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint
by reducing latent HIV reservoir and further demonstrated control of viral
load. Bionor currently retains full ownership rights to the HIV immunotherapy
Vacc-4x, i.e., the upside potential from partnering or licensing remains with
the company's shareholders. More information about Bionor is available
atwww.bionorpharma.com.

Important Information
The release is not for publication or distribution, in whole or in part
directly or indirectly, in or into Australia, Canada, Japan, Hong Kong or the
United States (including its territories and possessions, any state of the
United States and the District of Columbia).

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act. It is issued for information
purposes only, and does not constitute or form part of any offer or
solicitation to purchase or subscribe for securities, in the United States or
in any other jurisdiction. The securities mentioned herein have not been, and
will not be, registered under the United States Securities Act of 1933, as
amended (the "Securities Act"). The securities may not be offered or sold in
the United States except pursuant to an exemption from the registration
requirements of the Securities Act. The Company does not intend to register
any portion of the offering of the securities in the United States or to
conduct a public offering of the securities in the United States. Copies of
this announcement are not being made and may not be distributed or sent into
Australia, Canada, Japan, Hong Kong or the United States. The issue,
exercise, purchase or sale of subscription rights and the subscription or
purchase of shares in the Company are subject to specific legal or regulatory
restrictions in certain jurisdictions. Neither the Company nor SpareBank 1
Markets AS assumes any responsibility in the event there is a violation by
any person of such restrictions.

The distribution of this release may in certain jurisdictions be restricted by
law. Persons into whose possession this release comes should inform
themselves about and observe any such restrictions. Any failure to comply
with these restrictions may constitute a violation of the securities laws of
any such jurisdiction.

Solon_SEA20170126_PrimaryInsiderNotificationGrue

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Solon Eiendom ASA via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.